CoGenesis® BRCA-Pro

Hereditary breast and ovarian cancer test

CoGenesis® BRCA-Pro is an 11-gene test for hereditary breast and ovarian cancers. It includes genes linked to a higher chance of developing breast and ovarian cancer: BRCA1, BRCA2, ATM, TP53, CHEK2, PTEN, CDH1, STK11, PALB2, RAD51C, RAD51D genes. This test helps you to understand your risk level of developing breast and ovarian cancer throughout your lifetime.
Order Now

About hereditary breast cancer

1 in every 14 females in Hong Kong will have breast cancer in their lifetime.1
About 5% to 10% of breast cancers are hereditary.2
If you have a breast cancer gene mutation, your chance of getting breast cancer is 10 times higher than the general population.3

About hereditary ovarian cancer

About 10% to 15% of ovarian cancers are hereditary.2
If you have an ovarian cancer gene mutation, your chance of getting ovarian cancer is 50 times higher than the general population. 3

If you have tested positive for a breast and ovarian cancer gene mutation, it does not mean you definitely will have breast and ovarian cancer. However, your chance of getting breast and ovarian cancer will be higher than the general population.

What can you do if you belong to the high-risk population?

  • Start breast and ovarian cancer screening tests as soon as possible
  • Screen for breast and ovarian cancer more frequently
  • Closely watch out for any breast and ovarian cancer symptoms
  • Learn about options that reduce breast and ovarian cancer risk

Early detection genetic variation and prevention can reduce the risk of breast cancer by 90%, and risk of ovarian cancer by 85%.

​Hong Kong Hereditary Breast Cancer Family Registry. Hereditary Cancers.

Genetic testing should be made available to all newly diagnosed breast cancer patients.


Manahan, E. et al. Annals of Surgical Oncology, 26,10 (2019)

All women diagnosed with epithelial ovarian cancer should have germline genetic testing for BRCA1/2 and other ovarian cancer susceptibility genes.


Konstantinopoulos PA, et al. Journal of Clinical Oncology, 38,11 (2020)

A high accuracy standard

Steps Accuracy
DNA sequencing 99.9%
Variant calling – SNP >99%*
Variant calling – Indel >99%*
Variant Annotation 100%#

* Passed GenQA/UK NEQAS external quality assurance

# The interpretation of sequencing variants is based on the current understanding of the variants at the time it was observed, which may change over time as more information about the genes becomes available. Not all variants are represented in this report.

Source:

  1. Hong Kong Cancer Registry, Hospital Authority. Female Breast Cancer in 2018. Last updated: Oct 2020.
  2. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention.

More hereditary cancer test services